(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 2.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.02%.
Fortrea Holdings's revenue in 2026 is $2,759,900,000.On average, 14 Wall Street analysts forecast FTRE's revenue for 2026 to be $257,334,000,000, with the lowest FTRE revenue forecast at $236,174,400,000, and the highest FTRE revenue forecast at $271,656,000,000. On average, 12 Wall Street analysts forecast FTRE's revenue for 2027 to be $265,095,600,000, with the lowest FTRE revenue forecast at $242,272,800,000, and the highest FTRE revenue forecast at $282,559,200,000.
In 2028, FTRE is forecast to generate $274,335,600,000 in revenue, with the lowest revenue forecast at $257,149,200,000 and the highest revenue forecast at $288,657,600,000.